URSULA TOWNSEND: Open Payments
NPI 1245928001 · CAMDEN, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$818 in 32 payments from 9 companies in 2025. Trend: 2023 $74 · 2024 $748 · 2025 $818
Food & beverage: $818
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $266 |
| Alkermes, Inc. | 8 | $166 |
| E.R. Squibb & Sons, L.L.C. | 2 | $105 |
| Axsome Therapeutics, Inc. | 1 | $98 |
| Otsuka America Pharmaceutical, Inc. | 3 | $74 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $48 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
Products named: INGREZZA, ARISTADA, COBENFY, Auvelity, REXULTI, CAPLYTA, INVEGA SUSTENNA, Qelbree.
Industry payments across SC — which companies pay providers there.
